Clinical Trials
15
Active:8
Completed:3
Trial Phases
2 Phases
Phase 1:11
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (73.3%)Phase 3
4 (26.7%)First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: PBP1510 (400mg/16mL)
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 80
- Registration Number
- NCT05141149
- Locations
- 🇦🇺
Monash Health, Melbourne, Australia
🇺🇸Northwell Health / R.J. Zuckerberg Cancer Center, New Hyde Park, New York, United States
🇸🇬National Cancer Centre Singapore, Singapore, Singapore
A Phase 1, Double-blind, Randomized, Three-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of a Single Subcutaneous Dose of PBP1502, EU-Humira®, and US-Humira® in Healthy Male and Female Subjects
Phase 1
Suspended
- Conditions
- Healthy volunteers
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Prestige Biopharma Ltd
- Target Recruit Count
- 93
- Registration Number
- 2024-519145-30-00
- Locations
- 🇪🇸
Universidad Autonoma De Madrid, Madrid, Spain
A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 105
- Registration Number
- NCT03776240
- Locations
- 🇦🇺
Q Pharm, Brisbane, Australia
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
Phase 3
Active, not recruiting
- Conditions
- Non-small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 650
- Registration Number
- NCT03390686
- Locations
- 🇧🇾
Alexandrov Cancer Center, Minsk, Belarus
🇧🇬MHAT "Dr. Tota Venkova", AD, Gabrovo, Bulgaria
🇭🇷CHC Osijek, Osijek, Osijecko-baranjska, Croatia
To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 119
- Registration Number
- NCT03390673
- Locations
- 🇳🇿
Auckland Clinical Studies, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand
- Prev
- 1
- 2
- Next
News
No news found